Home   |  Kontaktandmed   |  Asukohad
Safe Infusion Therapy (ET)
 

Finantstagajärjed

Majanduslikud tagajärjed

Inimeste, eriti arenevate laste kokkupuutel DEHP-ga võivad olla tõsised tagajärjed tervisele, nagu ülal näidatud (vt Tagajärjed tervisele, joonis 14)
. Neil häiretel on olulised majanduslikud tagajärjed ning tõsisemad haigused raskendavad märkimisväärselt majanduslikke koormaid.

Joonis 16. DEHP ekspositsioonist tingitud tüsistuste tagajärjel tekkida võivate lisakulude prognoos. Iga tüsistusega kaasneda võivate kulude arvestamise hõlbustamiseks võeti kasutusele raskusastmed (Dean & Barber skaala 1).

Joonise 16 viited.

Sellel hüperlingil klõpsates lahkute meie veebilehelt. B. Braun ei ole avatava veebilehe omanik ega halda selle sisu.

1The Straits Times, Thu, Oct 29, 2009

2The costs of myocardial infarction-a longitudinal analysis using data from a large German health insurance company Reinhold T, Lindig C, N. Willich S, Brüggenjürgen B. Journal of Public Health 2011 19:6 (579-586)

2Cost of myocardial infarction to the Australian community: A prospective, multicentre survey Ioannides-Demos L.L., Makarounas-Kirchmann K, Stoelwinder J, McNeil JJ, Ashton E. Clinical Drug Investigation 2010 30:8 (533-543)

3Nephrol Dial Transplant (2009) 24: 3209–3215. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Gowrie Balasubramaniam, Edwina A. Brown, Andrew Davenport, Hugh Cairns, Barbara Cooper, Stanley L. S. Fan, Ken Farrington, Hugh Gallagher, Patrick Harnett, Sally Krausze and Simon Steddon.

4Prevalence rates and costs of metabolic syndrome and associated risk factors using employees' integrated laboratory data and health care claims. Birnbaum H.G., Mattson M.E., Kashima S., Williamson T.E. Journal of Occupational and Environmental Medicine 2011 53:1 (27-33)

4Health economics perspective of the components of the cardiometabolic syndrome Tamariz L., Palacio A., Florez H., Tamariz L., Palacio A., Yang Y., Parris D., Florez H., Tamariz L., Palacio A., Florez H., Ben-Joseph R.

4Journal of Clinical Hypertension 2010 12:7 (549-555)

5Long-term economic bene¦ts attributed to IVF-conceived children: A lifetime tax calculation. Connolly M.P., Pollard M.S., Hoorens S., Kaplan B.R., Oskowitz S.P., Silber S.J., Silber S.J. American Journal of Managed Care 2008 14:9 (598-604)

5Resource allocation of in vitro fertilization: A nationwide register-based cohort study. Klemetti R., Sevón T., Hemminki E., Gissler M., Sevón T., Hemminki E. BMC Health Services Research 2007 7 Article Number 210

6Economic Analysis of Infant vs Postpubertal Orchiopexy to Prevent Testicular Cancer. Hsieh M.H., Roth D.R., Meng M.V. Urology 2009 73:4 (776-781)

7Staged reconstruction of hypospadias with chordee: Outcome and costs. Svensson H, Reychman M, Åberg M, Troëng T, Svensson H. Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery 1997 31:1 (51-55)

7Proximal hypospadias comparative evaluation of staged urethroplasty (modi¦ed Thiersch Duplay followed by Mathieu) and single stage on-lay island §ap repair. Samuel M., Capps S., Worth A., Samuel M. European Urology 2001 40:4 (463-468)

8One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Mahoney E.M., Wang K., Cohen D.J., Hirsch A.T., Alberts M.J., Eagle K., Mosse F., Jackson J.D., Steg P.G., Bhatt D.L., REACH Registry Investigators Circulation. Cardiovascular quality and outcomes 2008 1:1 (38-45)

8Cost of atherothrombotic diseases - Myocardial infarction, ischaemic stroke and peripheral arterial occlusive disease - In Germany Brüggenjürgen B., Rupprecht H.-J., Spannagl M., Berger K., Ehlken B., Smala

Not all products are registered and approved for sale in all countries or regions. Indications of use may also vary by country and region. Product images are for reference only. Please contact your country representative for product availability and information.